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Summary
The c-Jun and c-Myc oncogenic transcription factors are highly unstable proteins due to polyubiquitination. Similar to
c-Myc, we report here that phosphorylation of c-Jun by GSK3 creates a high-affinity binding site for the E3 ligase Fbw7,
which targets c-Jun for polyubiquitination and proteasomal degradation. In keeping with this, we found that c-Jun levels
were inversely related to GSK3 activity in mammalian cells that had entered the cell cycle. Importantly, phosphorylation
of c-Jun by GSK3 requires a priming phosphorylation event at Ser-243. Ser-243 is mutated to phenylalanine in v-Jun and
allows it to escape recognition by Fbw7. These findings explain the enhanced stability and oncogenicity of v-Jun relative
to its cellular counterpart and reveal that GSK3 and Fbw7 coordinately regulate c-Jun and c-Myc.S I G N I F I C A N C E
Dysregulation of the c-Jun transcription factor can transform cells. The avian viral oncogene v-Jun lacks the c-Jun δ domain and
has two missense mutations at Ser-243 and Cys-269. We found that mutation of Ser-243, which is important for phosphorylation of
c-Jun by GSK3, prevents c-Jun from being earmarked for destruction by the Fbw7 ubiquitin ligase complex. Our results assign a
biological significance to the v-Jun point mutation and underscore the importance of the Fbw7-c-Jun interaction in the control of
cell proliferation. GSK3-dependent Fbw7 binding sites are also present in c-Myc and cyclin E, suggesting that decreased GSK3
activity in cancer cells, such as occurs with increased PI3K/Akt or Wnt signaling, would simultaneously activate c-Jun, c-Myc, and
cyclin E.Introduction
The c-Jun oncoprotein, which is a highly unstable transcription
factor, can heterodimerize with c-Fos to form AP-1 transcrip-
tion factor complexes (Shaulian and Karin, 2002). AP-1 has im-
portant functions in a wide range of cellular activities including
cellular proliferation, transformation, and death. For example,
c-Jun and its viral oncogene counterpart, v-Jun, cooperate
with Ha-Ras in malignant transformation of murine cells (Weiss
and Bohmann, 2004). Additionally, dysregulation of c-Jun has
been reported in many types of human cancer (Karin, 1995;
Shaulian and Karin, 2002; Weiss and Bohmann, 2004). Hence,
cellular c-Jun activity must be very tightly regulated, and there
is evidence that it is controlled by both transcriptional and
posttranslational mechanisms (Shaulian and Karin, 2002; Weiss
and Bohmann, 2004).
c-Jun shares many similarities with the oncoprotein c-Myc.
Both proteins play critical roles in driving cells through S phase,
and aberrant overexpression of either c-Jun or c-Myc leads to
apoptosis. Additionally, both are the products of immediate-
early genes whose mRNAs transiently peak at the beginning of
the G0-G1 transition and then rapidly decrease. Moreover, the
stability of both c-Jun and c-Myc are tightly regulated after cellCANCER CELL : JULY 2005 · VOL. 8 · COPYRIGHT © 2005 ELSEVIER INC.cycle reentry because of polyubiquitination (Gregory and Hann,
2000; Salghetti et al., 1999; Salvat et al., 1998; Treier et al.,
1994). The transforming ability of v-Jun, the viral counterpart
of c-Jun, is due at least partly to increased stability (Weiss and
Bohmann, 2004). Several groups showed that c-Myc is polyu-
biquitinated in a GSK3-dependent manner by an SCF complex
containing the F box protein Fbw7 (also called hCdc4, Sel-10,
and Fbxw7) (Moberg et al., 2004; Welcker et al., 2004; Yada et
al., 2004). How c-Jun polyubiquitination is achieved following
mitogenic stimulation, and how this process is subverted by
v-Jun, are not understood. This prompted us to examine
whether c-Jun and c-Myc are targeted for degradation in the
same manner and whether this process is altered by the muta-
tions present in v-Jun.
Notably, a recent paper by Nateri and coworkers reported
that phosphorylation of the c-Jun N terminus by JNK in neu-
ronal cells targets c-Jun for polyubiquitination by Fbw7 (Nateri
et al., 2004). However, this conclusion seemingly contradicts
earlier studies demonstrating that JNK phosphorylation pro-
tects c-Jun from ubiquitination and subsequent degradation
(Fuchs et al., 1997; Musti et al., 1997). Here, we show that
phosphorylation of the c-Jun C terminus by GSK3 leads to
Fbw7 binding and destruction of c-Jun. Moreover, this site isDOI 10.1016/j.ccr.2005.06.005 25
A R T I C L Edestroyed by a v-Jun point mutation, leading to c-Jun stabiliza-
tion. In contrast, deletion of the JNK docking site within
c-Jun, called the δ domain, or elimination of the c-Jun JNK
phosphorylation sites, did not affect the interaction between
Fbw7 and c-Jun and did not enhance c-Jun stability. In keep-
ing with these considerations, we found that c-Jun levels are
inversely correlated with GSK3 activity, but not JNK activity, as
resting cells reenter the cell cycle. These findings support that
c-Jun and c-Myc are coordinately regulated by GSK3 and
Fbw7.
Results
c-Jun contains a sequence that is similar to the c-Myc
Fbw7 binding site
Using the Prosite Motif Scan Program, we found that c-Jun
contains a collinear sequence that is highly similar to the Fbw7
binding sites in c-Myc, cyclin E, and Notch1 (Ye et al., 2004)
(Figure 1A). Importantly, the Fbw7 binding site in c-Myc andFigure 1. Binding of Fbw7 to a c-Jun degron containing phosphothreonine 239 and phosphoserine 243
A: Sequence alignment of c-Jun with cyclin E, Notch1, and c-Myc Fbw7 phosphodegrons.
B: Sequences of biotinylated c-Jun and c-Myc peptides used in Fbw7 binding assays.
C–E: Autoradiograms showing recovery of 35S-labeled F box proteins bound to indicated biotinylated peptides. IN, input (10% in [C]; 20% in [D] and [E]). In
E, increasing amounts of nonbiotinylated c-Jun or c-Myc phosphopeptides were added to the binding reactions (5-, 16-, or 50-fold excess, as indicated
by the triangles).
F–H: Immunoblot (IB) analysis of whole-cell extracts (WCE) and immunoprecipitates (IP) derived from HeLa cells (F and G) or 293T cells (H) transfected to
produce HA-Fbw7α and the indicated Myc-tagged (F) or Flag-tagged (G) c-Jun proteins. GSK3 inhibitor was added where indicated in G and H.26the putative Fbw7 binding site in c-Jun are highly conserved
through evolution (see Figures S1A and S1B in the Supplemen-
tal Data available with this article online). Interestingly, both
cyclin E (Welcker et al., 2003) and c-Myc (Welcker et al., 2004)
must be phosphorylated by GSK3 for efficient recognition by
Fbw7, and this c-Jun sequence contains a well-characterized
GSK3 site (Thr-239) (Boyle et al., 1991; Morton et al., 2003).
Moreover, phosphorylation by GSK3 requires a priming phos-
phorylation event at position +4 (Doble and Woodgett, 2003),
and c-Jun Ser-243 is mutated to phenylalanine in v-Jun (Maki
et al., 1987). ERK1 and DYRK1 can phosphorylate Ser-243
in vitro, but whether they do so in vivo is not known (Morton
et al., 2003).
Phosphothreonine 239 and phosphoserine 243
are necessary for interaction of c-Jun
with Fbw7 both in vivo and in vitro
To determine the significance of the observation that c-Jun
contains an almost identical central phosphorylation domainCANCER CELL : JULY 2005
A R T I C L EFigure 2. Lack of binding of Fbw7 to c-Jun JNK phosphorylation sites
A: Sequences of biotinylated c-Jun peptides containing JNK phosphorylation sites.
B and C: Autoradiograms showing recovery of 35S-labeled Fbw7 bound to indicated biotinylated peptides. IN, 20% input. In C, increasing amounts of the
indicated nonbiotinylated c-Jun phosphopeptides were added to the binding reactions (5-, 16-, or 50-fold excess, as indicated by the triangles).
D: Immunoblot (IB) analysis of whole-cell extracts (WCE) and anti-Flag immunoprecipitates (IP) derived from HeLa cells transfected to produce the indi-
cated Flag-tagged c-Jun and HA-Fbw7α proteins. Note that the epitope tag was placed at the C terminus of Fbw7 to avoid interfering with the recognition
of the c-Jun N terminus by JNK.
E: IB analysis of HeLa cells transfected to produce the indicated Flag-tagged c-Jun proteins and treated with DMSO or the indicated kinase inhibitors
(25 M).(CPD) as c-Myc (see Figure 1A), we performed Fbw7 binding
assays with immobilized synthetic peptides. Fbw7 bound to a
peptide corresponding to c-Jun residues 229–253, which
spans the putative Fbw7 binding site, provided both Thr-239
and Ser-243 were phosphorylated and the Fbw7 WD40 repeat/
substrate binding domain was intact (Figures 1B and 1C and
Figures S1C and S1D). In particular, Fbw7 did not recognize
peptides containing the v-Jun mutation at residue Ser-243, re-
gardless of the phosphorylation status of Thr-239 (Figure 1C).
The doubly phosphorylated c-Jun peptide was recognized by
all three Fbw7 isoforms (α, β, γ) but not by a panel of unrelated
F box proteins (Figure 1D and data not shown). Cross-competi-
tion experiments with the homologous c-Myc phosphopeptide
indicated that both c-Jun and c-Myc bind to the same site on
Fbw7 (Figure 1E). Disruption of Fbw7 binding in these competi-
tion assays was specific, because it was not observed with
c-Jun-derived phosphopeptides that do not bind to Fbw7 (see,CANCER CELL : JULY 2005for example, Figure 2C). Consistent with these in vitro studies,
Fbw7 bound to c-Jun in reciprocal coimmunoprecipitation ex-
periments after proteasomal blockade unless Thr-239 or Ser-
243 was replaced with alanine or phenylalanine, respectively
(Figure 1F and Figure S2). In addition, we found that pharma-
cological inhibition of GSK3 activity blocked the interaction of
HA-Fbw7 with exogenously expressed Flag-c-Jun (Figure 1G)
as well as with endogenous c-Jun (Figure 1H) in cells treated
with the proteasomal inhibitor MG132. To our knowledge, there
are no antibodies available that are capable of recognizing en-
dogenous Fbw7.
JNK phosphorylation is not required for c-Jun
to interact with Fbw7
v-Jun lacks a region called the δ domain, which is a JNK dock-
ing site, in addition to the S243F and C269S point mutations.
Deletion of the δ domain renders the c-Jun transactivation do-27
A R T I C L EFigure 3. Phosphorylation of Thr-239 and Ser-243 is required for Fbw7-mediated c-Jun disappearance
A–D: Immunoblot analysis of 293T cells transfected to produce the indicated c-Jun and Fbw7 proteins in the presence or absence of HA-GSK3β. A plasmid
encoding GFP was used to control for transfection efficiency.main constitutively active by preventing the binding of an
HDAC3-containing repressor complex (Weiss et al., 2003). The
S243F mutation, but not deletion of the δ domain, abrogated
Fbw7 binding to c-Jun (Figure 1F). These findings support the
idea that Fbw7 binds to c-Jun in GSK3-dependent manner and
that this interaction is disrupted by the v-Jun S234F point mu-
tation. While this work was in progress, however, Nateri et al.
reported that phosphorylation of N-terminal sites within c-Jun
by JNK creates Fbw7 binding sites (Nateri et al., 2004), in ap-
parent disagreement with our finding that the δ domain is dis-
pensable for Fbw7 binding (Figure 1F) and with earlier reports
that phosphorylation by JNK protects c-Jun from polyubiquiti-
nation (Fuchs et al., 1997; Musti et al., 1997). Moreover, neither
of the sites identified by Nateri et al. closely resembles known
Fbw7 binding sequences (compare Figures 2A and 1A).
To pursue this further, we repeated our Fbw7 binding assays
with the Fbw7 binding c-Jun phosphopeptides described by
Nateri et al. Neither peptide, which spans c-Jun JNK phos-
phorylation sites at residues 63 and 73 or 91 and 93, respec-
tively, bound to Fbw7 under our assay conditions (Figures 2B
and 2C and Figure S1E). Moreover, elimination of these phos-
phorylation sites in the context of full-length c-Jun did not
measurably affect Fbw7 binding (Figure 2D) and did not indi-
rectly affect the phosphorylation of c-Jun on Thr-239 and Ser-
243 (Figure 2E). Conversely, elimination of the GSK3 sites did28not affect the phosphorylation of c-Jun on Ser-63 and Ser-73
(Figure 2E and data not shown). We conclude that binding of
Fbw7 to c-Jun occurs primarily via the GSK3-dependent motif.
Phosphorylation of Thr-239 and Ser-243 is required
for Fbw7-mediated c-Jun degradation
Having demonstrated that Fbw7 binds to c-Jun in a GSK3-
dependent manner, we next asked whether the binding of
Fbw7 could alter c-Jun abundance. As shown in Figure 3A,
cotransfection of both Fbw7α and constitutively active GSK3
greatly decreased wild-type c-Jun protein levels but did not
affect a c-Jun variant in which both Thr-239 and Ser-243 were
mutated (AF-Jun). Similar results were observed with Fbw7β
and Fbw7γ (Figure 3B). The potential effects of GSK3 might
be underestimated in these assays because the GSK3 priming
kinase(s) could be limiting under these conditions. Mutation of
either Thr-239 or Ser-243 to alanine allowed c-Jun to escape
degradation by Fbw7 (Figure 3C), excluding that the results
obtained with AF-Jun were due to conformational changes in-
duced by the phenylalanine substitution at Ser-243. Moreover,
deletion of the δ domain, in contrast to mutation of the GSK3
sites, did not allow c-Jun protein to escape Fbw7-mediated
protein degradation (Figure 3D). Collectively, these results indi-
cated that phosphorylation of both Thr-239 and Ser-243 is re-
quired for Fbw7-mediated c-Jun degradation.CANCER CELL : JULY 2005
A R T I C L EFigure 4. GSK3 and Fbw7 promote c-Jun ubiquitination and degradation in vivo
A: Immunoblot (IB) analysis of whole-cell extracts (WCE) and anti-Flag immunoprecipitates (IP) of HeLa cells treated with the proteasomal inhibitor MG132
after transfection with the indicated plasmids.
B and C: Immunoblot analysis (IB) of 293T cells transfected to produce the indicated Flag-Fbw7, HA-GSKβ, and Flag-c-Jun proteins along with a plasmid
encoding GFP. In B, MG132 was present for 12 hr where indicated. In C, cell extracts were prepared at the indicated time points after the cells were
treated with Cycloheximide.Promotion of c-Jun ubiquitination by Fbw7 in vivo
in a GSK3 phosphorylation-dependent manner
To investigate whether Fbw7 could promote c-Jun ubiquitina-
tion in a GSK3-dependent manner, we performed in vivo ubiq-
uitination assays. Cotransfection with Fbw7 led to increased
polyubiquitination of wild-type c-Jun, but not AF-Jun (Figure
4A). Furthermore, this effect was magnified in the presence of
a constitutively active form of GSK3β. In contrast, elimination
of the JNK phosphorylation sites did not affect c-Jun polyubiq-
uitination by Fbw7 (Figure S3). We have been unable to poly-
ubiquitinate wild-type c-Jun with Fbw7 (with or without GSK3)
using purified components in vitro under conditions when
cyclin E was efficiently ubiquitinated. In pilot experiments,
however, we found that Fbw7 produced in wheat germ extract,
in contrast to rabbit reticulocyte lysate, did not bind to c-Jun
(Figure S1F). Reconstitution of c-Jun polyubiquitination by
Fbw7 and GSK3 in vitro will require the identification of the
factor(s) responsible for this discrepancy. These factors might,
for example, bridge c-Jun and Fbw7 or modify Fbw7. The ef-
fect of Fbw7 on c-Jun levels (Figure 3) could be blocked with
proteasome inhibitors (Figure 4B and data not shown) and was
due to changes in c-Jun half-life, as measured in Cyclohexi-
mide chase experiments (Figure 4C), further arguing that the
effects of Fbw7 on c-Jun levels is due to polyubiquitination and
proteasomal degradation.
c-Jun protein level inversely correlates with GSK3,
but not JNK, activity during cell cycle progression
Next, we monitored the behavior of endogenous c-Jun after
serum starvation and release. Human cells contain two GSK3
genes, called GSK3α and GSK3β, that are highly similar with
respect to sequence and function. It is known that GSK3 is
active in serum-starved (quiescent) cells and transiently inacti-CANCER CELL : JULY 2005vated by phosphorylation on Ser-21 of GSK3α and Ser-9 of
GSK3β in early G1 after serum readdition owing to PI3K/Akt
pathway activation (Kim and Kimmel, 2000; Liang and Slinger-
land, 2003). Hence, Akt activity is inversely related to GSK3
activity. As expected, c-Jun, like c-Myc and cyclin E, was un-
detectable in serum-starved cells, because these genes are not
transcribed under these conditions (Figure 5A). All three pro-
teins were rapidly induced (within 4 hr) after serum refeeding.
Importantly, all three proteins began to disappear 8–16 hr after
serum readdition, coincident with the activation of GSK3 as
determined by a decrease in the inhibitory phosphate (phos-
phoserine 9) on GSK3β and increased phosphorylation of the
GSK3 substrates glycogen synthase (Figure 5A) and Rb-
related protein p130 (Figure S4). During this period, cells began
to enter S phase (Figure 5B). In contrast, disappearance of
c-Jun did not coincide with the appearance of activated, phos-
phorylated JNK (Figure 5A). JNK, like Akt, is regulated by the
Ras pathway and is transiently activated in early G1 phase
(Figure 5A; 4 hr time point) (Downward, 1997). Phosphorylation
of c-Jun on the JNK sites Ser-63 and Ser-73 preceded the ap-
pearance of Ser-243 phosphorylation, which is believed to
prime GSK3-dependent phosphorylation of Thr-239. Unfortu-
nately, the previously reported antibodies capable of recogniz-
ing the phosphoT239 site in endogenous c-Jun have been ex-
hausted (J. Hastie, personal communication) (Morton et al.,
2003). Thus, c-Jun disappearance in this experimental para-
digm coincides with GSK3 activation but not JNK activation
(See Figure 8).
Depletion of GSK3 or Fbw7 results
in accumulation of c-Jun
To investigate further the contribution of GSK3 and Fbw7 to
endogenous c-Jun turnover in vivo, we monitored c-Jun levels29
A R T I C L EFigure 5. Endogenous c-Jun levels inversely correlate with GSK3 during cell
cycle progression
Immunoblot (A) and FACS (B) analysis of T98G cells induced to enter G0 by
serum starvation for 72 hr and then released for the indicated time periods.after inactivating these proteins. Downregulation of Fbw7 in
HeLa cells by RNAi resulted in dramatic increase in the steady
state level of c-Jun, c-Myc, and cyclin E (see Figures 6A and
6B), which was accompanied by an increase in the percentage
of cells in S phase (Figure S5A). Moreover, the increase in S
cell population by Fbw7 depletion is partially due to c-Jun in-
duction, because concurrent downregulation of c-Jun by RNAi
treatment greatly reduced S phase population in Fbw7-
depleted HeLa cells (see Figures S5B and S5C). Similarly, inhi-
bition of GSK3 with siRNA (Figure 7A) or small molecule GSK3
antagonists (Figures 7B and 7C and Figure S6) led to the accu-
mulation of endogenous c-Jun. The effects of inhibiting Fbw7
or GSK3 were also observed after prior cell synchronization,
indicating that the observed increases in c-Jun were not an
indirect effect of cell cycle changes induced by these agents
(Figures 6B and 7C). In contrast, c-Jun was not increased in
cells treated with a JNK inhibitor (Figure 7D and Figure S6D).
Phosphorylation of c-Jun on Ser-63 and Ser-73 was, as ex-
pected, decreased by the JNK inhibitor but not decreased by
the GSK3 inhibitor. Conversely, the GSK3 inhibitor did not de-
crease Ser-63 or Ser-73 phosphorylation. Pulse-chase experi-
ments using synchronized T98G cells confirmed that endoge-
nous c-Jun half-life was increased with the GSK3 inhibitor and
diminished with the JNK inhibitor (Figures 7E and 7F).
Discussion
Collectively, these results support that Fbw7 regulates c-Jun
stability in a GSK3-dependent manner under physiological
conditions (see Figure 8). In early G1 phase, growth stimulation
leads to a rapid induction of Ras activity and accumulation of
PI3K/Akt kinase activities. This leads to phosphorylation of
GSK3β on Ser-9 and GSK3α on Ser-21, which inhibits GSK3
kinase activity. As illustrated in Figure 5A, low GSK3 activity at
early G1 phase after serum addition correlates with high abun-
dance of c-Jun. In late G1 phase, Akt activity significantly30Figure 6. Depletion of Fbw7 results in accumulation of c-Jun
Immunoblot analysis of asynchronous (A) or synchronized (B) HeLa cells
transfected with the indicated siRNAs.drops due to shutdown of Ras activity. This leads to reactiva-
tion of GSK3 activity and a decrease in c-Jun abundance. An
inverse correlation between c-Myc abundance and GSK3 ac-
tivity has also been observed (Sears et al., 2000). These obser-
vations support the notion that the timely biphasic control of
GSK3 activity downstream of the Ras/PI3K/Akt pathway re-
stricts the accumulation of c-Myc and c-Jun protein to a rela-
tively narrow window in G1. In particular, both proteins are trig-
gered for degradation by GSK3 phosphorylation in later G1
phase once they have accomplished their duties.
The recent suggestion that phosphorylation of c-Jun by JNK
triggers c-Jun degradation (Nateri et al., 2004) contradicts early
reports indicating that phosphorylation of c-Jun by JNK1 pro-
tects it from ubiquitin-mediated degradation (Musti et al.,
1997). Recent studies with MEFs deficient in either Jnk1, Jnk2,
or both, are also informative in this regard. From these studies,
it appears that JNK1 is the primary kinase capable of phos-
phorylating c-Jun after serum stimulation and that this phos-
phorylation event stabilizes c-Jun (Sabapathy et al., 2004). In
particular, c-Jun is hypophosphorylated, and its levels are de-
creased, in Jnk1−/− MEFs as well as Jnk1−/−/Jnk2−/− MEFs (Sa-
bapathy et al., 2004). It is true that JNK2 can promote c-Jun
degradation in serum-starved cells, but this effect does not re-
quire JNK2 kinase activity and is not linked to c-Jun phosphor-
ylation (Sabapathy et al., 2004). Moreover, we demonstrated
that in several cell lines inhibition of GSK3 activity, but not inhi-
bition of JNK activity, leads to increased c-Jun protein level
(Figure 7D and Figure S6D). These results are in agreement
with our observation that c-Jun levels are high when Akt and
JNK are active and fall during a period when GSK3 becomes
active and JNK becomes inactive (Figure 8).
Although these considerations suggest that JNK protects
c-Jun from degradation, we cannot formally exclude the possi-
bility that JNK targets c-Jun for destruction in very specific
contexts. It should be noted, however, that many of the cell-
based experiments reported by Nateri and coworkers used
293T cells (Nateri et al., 2004). Therefore, cell line differences
are unlikely to account for our discrepant results. Their results
using neuronal cells are consistent with a role of Fbw7 in c-Jun
degradation (upon which we agree) and earlier reports showing
that JNK is required for c-Jun-dependent apoptosis in such
cells but did not prove that JNK targets c-Jun for degradationCANCER CELL : JULY 2005
A R T I C L EFigure 7. Depletion of GSK3 results in accumulation of c-Jun
A–C: Immunoblots of HeLa cells transfected with the indicated siRNAs (A) or treated with the GSK3 inhibitor VIII (25 M) (B and C). In C, GSK3 inhibitor VIII
or MG132 was added to asynchronously growing cells or to cells synchronized in S phase by the addition of aphidicolin.
D: Immunoblots of T98G cells treated with the GSK3 inhibitor VIII (25 M) or JNK inhibitor (25 M).
E and F: Pulse-chase analysis of T98G cells. T98G cells were first synchronized at G0 by serum starvation and then refed serum. Four hours later, the cells
were treated with GSK3 inhibitor, JNK inhibitor, or vehicle. E: Autoradiograms of anti-c-Jun immunoprecipitates obtained at indicated time points during
chase. F: Quantitation of band intensities in E.in this setting. Nonetheless, it is possible that Fbw7 interacts
with the c-Jun JNK phosphorylation sites under specific cir-
cumstances not examined here. It is also possible that JNK
can, directly or indirectly, affect other c-Jun ubiquitin ligases.
In this regard, both Itch (Gao et al., 2004) and COP1 (Wertz et
al., 2004) have also been implicated as c-Jun ubiquitin ligases.
Ubiquitination of c-Jun in T-lymphocytes by Itch is enhanced
after Itch is phosphorylated by JNK (Gao et al., 2004). There is
ample precedence for the control of a single protein by multiple
ubiquitin ligases that act in different contexts and in response
to different signals (Dornan et al., 2004; Lai, 2002).
GSK3 inhibitors have been shown to block neuronal apopto-
sis mediated by c-Jun (Hongisto et al., 2003), in apparent dis-
agreement with our finding that GSK3 inhibitors upregulate
c-Jun in a variety of cells including PC12 cells, which are a
standard model for neuronal apoptosis. However, GSK3 has
multiple cellular targets, and the effects of GSK3 inhibitors on
neuronal apoptosis appear to be complex. In one study, GSK3
inhibitors blocked signals downstream of c-Jun and may have
also interfered with upstream apoptotic signals generated by
NGF withdrawal (Hongisto et al., 2003).
Our findings, together with an earlier report that phosphory-
lation of c-Jun by GSK3 on Thr-239 decreases its DNA binding
activity, provide a plausible explanation for the enhanced onco-
genicity of v-Jun relative to c-Jun (Boyle et al., 1991). However,
there have been conflicting results with respect to the contribu-
tion of the Ser-243 mutation to transformation by v-Jun. One
group reported that introduction of the S243F mutation intoCANCER CELL : JULY 2005c-Jun causes a slight increase in transformation in vitro (Bos
et al., 1990) but is sufficient to promote tumorigenesis in vivo
(Wong et al., 1992). Another group reported that introduction
of the Ser-243 mutation or deletion of the δ domain in c-Jun is
sufficient to promote transformation by c-Jun in vitro (Basso et
al., 2000). Likewise, we found that the AF mutation increases
transformation by c-Jun in soft agar assays (W.W. and W.G.K.,
unpublished data). We predict that the importance of the Ser-
243 mutation to v-Jun-dependent transformation will be influ-
enced by the GSK3 activity of the recipient cells.
The observed inverse correlation of c-Jun, c-Myc, and cyclin
E levels with GSK3 activity after cell cycle entry suggests that
dual phosphorylation by both priming and GSK3 kinases con-
stitutes a failsafe mechanism, analogous to a two-key lock
system, that accurately regulates the degradation of these
proteins. Our findings indicate that the S phase-promoting pro-
teins c-Myc, c-Jun, and cyclin E share similar signaling ele-
ments, are polyubiquitinated by the same ubiquitin ligase, and
therefore exhibit similar periodicity during cell cycle pro-
gression. This highly orchestrated cell cycle dependence en-
sures that these proteins accumulate to levels sufficient to pro-
mote S phase entry in response to specific signals and are
then quickly degraded to avoid aberrant DNA replication and
genomic instability. The requirement for two phosphorylation
events might minimize the likelihood that one of these proteins
would be prematurely degraded once cells had passed the re-
striction (R) point in late G1 and become committed to DNA
replication.31
A R T I C L EFigure 8. Proposed model for pathways that control c-Jun accumulation
and degradation during G0 to S phase transition
In early G1 phase, both Akt and JNK activity are activated by Ras after
serum stimulation. Activated PI3K/Akt pathway results in inhibitory phos-
phorylation of GSK3. As cells progress to mid-G1 phase, Ras activity sub-
sides, leading to decreased Akt activity. This permits the reactivation of
GSK3, which in turn phosphorylates c-Jun and thereby triggers c-Jun deg-
radation.Our findings suggest that GSK3 and Fbw7 are master regu-
lators of a number of proteins that play critical roles in cell pro-
liferation and hence would be suspected to play roles in human
cancer. Although GSK3 mutations have not been observed in
cancer, it is noteworthy that both the Wnt pathway and the
PI3K/Akt pathway, which are frequently activated in cancer
cells, impinge upon and inhibit GSK3 (Woodgett, 2001). In ad-
dition, we note that 4q32, the genetic locus carries the Fbw7
tumor suppressor gene, is deleted in many types of tumors,
and point mutations affecting Fbw7 have been described in
breast, colorectal, and endometrial cancers (Rajagopalan et al.,
2004; Spruck et al., 2002). Our finding that the GSK3-depen-
dent interaction of Fbw7 with c-Jun is disrupted by the onco-
genic v-Jun point mutation provides further genetic evidence
that GSK3 and Fbw7 operate to suppress transformation.
Experimental procedures
Plasmids
c-jun cDNA was amplified by PCR reaction from an image clone (ATCC;
catalog no. MGC-3338) with primers that introduced an N-terminal Myc or
C-terminal Flag epitope tag and subcloned into pcDNA3 expression vector
(Invitrogen). c-Jun mutants were generated using the QuikChange Site-
Directed Mutagenesis Kit (Stratagene). HA-tagged Fbw7 α isoform was a
kind gift of Prof. Keiichi Nakayama. Flag-tagged Fbw7 β and γ isoforms
were obtained from Dr. Bruce Clurman. Fbw4, Fbw5, and HA-tagged
GSK3β S9F construct were obtained from Dr. James DeCaprio. The cDNAs
used in these studies were all validated by DNA sequencing.
Antibodies
Anti-c-Jun antibody (9162), anti-phospho-c-Jun (Ser-63) antibody (9261),
anti-phospho-c-Jun (Ser-73) antibody (9164), polyclonal anti-Myc epitope
antibody (2272), anti-phospho-GSK3β (Ser-9) antibody (9336), anti-Akt anti-
body (9272), anti-phospho-Akt antibody (4051), anti-JNK antibody (9252),
and anti-phospho-JNK antibody (9255) were from Cell Signaling. Anti-Cdk2
antibody (SC-163), anti-p27 antibody (SC-528), polyclonal anti-HA antibody
(SC-805), monoclonal anti-Myc epitope (SC-40), anti-cyclin E antibody (SC-
247), anti-p130 antibody (sc-317), and anti-c-Jun (H-79) antibody were from
Santa Cruz. Anti-tubulin antibody (T-5168), polyclonal anti-Flag antibody
(F-7425), monoclonal anti-Flag antibody (F-3165), peroxidase-conjugated
anti-mouse secondary antibody (A4416), and anti-rabbit antibody (A4914)
were from Sigma. Anti-GSK3 α/β antibody (368662) was from Calbiochem.32Anti-GFP antibody (632380) was from Invitrogen. Anti-phospho-glycogen
synthase (Ser-641/645) antibody (PB-012) was from Kinasource. Anti-phos-
pho-p130 was a gift from Dr. James DeCaprio. Anti-phospho-c-Jun (Ser-
243) and (Thr-239) antibodies were from Dr. James Hastie.
SiRNAs
Fbw7 siRNA oligo (sense, 5#-AACCUUCUCUGGAGAGAGAAAUG-3#) and
c-jun siRNA oligos c-jun(1) (sense, 5#-AACGACCUUCUAUGACGAUGC-3#)
and c-jun(2) (sense, 5#-AAGAACUCGGACCUCCUCACC-3#) were purchased
from Dharmacon; GSK3α siRNA oligo (6312) and GSK3 α/β siRNA oligo
(6301) were purchased from Cell Signaling. GSK3β siRNA oligo was pur-
chased from Ambion (51012).
Cell culture
Cell culture including synchronization and transfection (plasmid or siRNA)
was as described previously (Wei et al., 2004). Where indicated, GSK3β
inhibitor VIII (Calbiochem), JNK inhibitor SP600125 (Sigma), MG132 (Calbio-
chem), or LiCl (Sigma) was added to the cell culture media.
c-Jun binding assays
Peptides were synthesized by Keck Biotechnology Resource Center of Yale
University and dissolved in PBS solution. Peptide (1 g) was preloaded
onto 30 l of streptavidin agarose and then incubated with 5 l of 35S-
labeled Fbw7 in vitro translate in 500 l NETN buffer for 1 hr at 4°C. After
five washes with NETN buffer, bound proteins were eluted by boiling in
sample buffer, resolved by SDS-PAGE, and detected by autoradiography.
Protein degradation, polyubiquitination, and pulse-chase analysis
Cells were transfected with a plasmid encoding a Flag epitope-tagged ver-
sion of the protein of interest along with a plasmid encoding GFP. For half-
life studies, Cycloheximide (200 g/ml; Sigma) was added to the media 48
hr later. At various time points thereafter, cells were removed and protein
abundance was measured by immunoblot analysis. For ubiquitination as-
says, the transfection mix also contained a plasmid encoding HA-ubiquitin.
Thirty-six hours after transfection, the proteasome inhibitor MG132 (30 M)
was added. Six hours later, anti-Flag immunoprecipitates were recovered
and immunoblotted with anti-HA antibody. For pulse-chase experiments,
T98G cells were first serum starved into quiescence for 72 hr. Four hours
after readdition of serum, GSK3 or JNK inhibitor was added to the medium
for an additional 6 hr. Cells were metabolically labeled for 20 min and then
chased exactly as described previously (Wei et al., 2004). Cell lysates were
incubated with anti-c-Jun antibody (SC-1694AC, Santa Cruz) overnight at
4°C. Immunoprecipitates were washed six times in NETN buffer and ana-
lyzed by SDS-PAGE.
Supplemental data
The Supplemental Data include six supplemental figures and can be found
with this article online at http://www.cancercell.org/cgi/content/full/8/1/25/
DC1/.
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